Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04632940 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD
A Phase 3 study, sponsored by Kyntra Bio.
- Terminated
- Registry status
- Phase 3
- Development phase
- 73
- Enrollment target
NCT04632940 is a Phase 3 study that was terminated before completion, run by Kyntra Bio. The registered enrollment target is 73 participants.
The verdict
NCT04632940, a Phase 3 study, was terminated before completion, sponsored by Kyntra Bio.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 73 participants
- Enrollment target
Study Summary
To evaluate the efficacy and safety of pamrevlumab versus placebo in combination with systemic corticosteroids administered every 2 weeks in ambulatory participants with Duchenne muscular dystrophy (DMD) (age 6 to \<12 years).
Interventions
- DRUG Placebo
- DRUG Corticosteroids
- DRUG Pamrevlumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2021-03-03 |
| Est. Completion | 2023-12-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04632940
The ClinicalTrials.gov registry entry for NCT04632940 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyntra Bio, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04632940 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04632940 about?
NCT04632940 is a clinical study titled "Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD". To evaluate the efficacy and safety of pamrevlumab versus placebo in combination with systemic corticosteroids administered every 2 weeks in ambulatory participants with Duchenne muscular dystrophy (DMD) (age 6 to \<12 years).
What is the current status of trial NCT04632940?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 73 participants. The study started on 2021-03-03. Estimated completion is 2023-12-14.
What interventions are being tested in trial NCT04632940?
The interventions under investigation include: Placebo (DRUG), Corticosteroids (DRUG), Pamrevlumab (DRUG).
Who is sponsoring clinical trial NCT04632940?
This trial is sponsored by Kyntra Bio, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.